Biocryst Pharma Inc (BCRX) is trading 21% higher at $13.45 today.

Biocryst Pharma Inc has been trading between a 52-week high of $19.99 and a 52-week low of $7.61. The stock has a market cap of $2.5 Billion.

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever.

BioCryst Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Seeking Alpha 08-04-22

BioCryst Pharmaceuticals GAAP EPS of -$0.32 beats by $0.03, revenue of $65.53M beats by $1.7M
Seeking Alpha 08-04-22

BioCryst Pharmaceuticals Q2 2022 Earnings Preview
Seeking Alpha 08-03-22

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Could Soar To Much Higher Prices In Coming Months
Marketing Sentinel 07-26-22

BioCryst Pharmaceuticals: Waiting For Clarity (NASDAQ:BCRX)
Seeking Alpha 07-25-22